Sleep and Alzheimer disease
Alzheimer's disease (AD) is a neurodegenerative disorder that affects older adults and is the most frequent cause of dementia [1] . It is characterized by progressive loss of cognitive abilities and other neurobehavioral manifestations, caused by neuritic plaques and extracellular deposits mainly of amyloid-β and intracellular neurofibrillary tangles. According to the International Working Group, in its typical course, AD is characterized by a gradual and progressive impairment in memory that has to be accompanied by at least one of the following in vivo biomarkers: a decreased amyloid-β together with increased T-tau or P-tau in the cerebrospinal fluid (CSF), increased tracer retention on amyloid positron emission tomography (PET), or the presence of an AD autosomal dominant mutation in presenilin 1 and 2 genes (PSEN1 and PSEN2) or in amyloid pecursor protein (APP) [2] .
Along with typical neuropsychological impairments and pathological signs, sleep disturbances are common in patients with AD [3] . There is evidence that impaired sleep can influence the progression of dementia and that insomnia might be a risk factor for the progression even the development of AD [4] . In particular, it has been demonstrated that disruption of slow wave sleep (SWS) is associated with increased levels of amyloid-β, the major protein abnormality in the neurodegenerative process that leads to AD [5••] . It is possible that accumulation of amyloid-β damages the generation of SWS which in turns impairs long-term hippocampus-dependent memory consolidation [6••] .
Although current literature on sleep and dementia has been focused on SWS, a recent study highlighted the potential importance of rapid eye movement (REM) sleep and dementia. In a longitudinal study, Pase and collaborators [7•] followed up 321 subjects aged over 60 for a maximum of 19 years (mean 12 ± 5). The authors found that reduced REM sleep percentage and longer REM sleep latency were associated with an increased risk for developing dementia. Each percentage reduction in REM sleep was associated with a 9% increase of risk. Stages of non-REM sleep were not associated with incidence of dementia. Since cholinergic neurons are highly activated during REM sleep, but not SWS, and a loss of cholinergic functioning is a feature of AD, there is biological support for an association between altered REM sleep and the risk of dementia.
From a clinical perspective, the assessment of sleep quality and quantity is fundamental for the management of patients with AD. This evaluation should be carried out by interviews with both patients and caregivers since AD patients could have reduced ability to report their symptoms. Not surprisingly, there are discrepancies across studies that subjectively evaluated the presence of sleep disorders in AD patients: some studies reported that up to 80% of AD patients considered their sleep as satisfactory [8] , whereas other studies reported satisfaction ranging from 11 to 45% [3] . Only carers can give valid information about irregular sleep-wake patterns, increased number of nocturnal awakenings, and early morning awakenings [9] .
In view of the inconsistency of subjective reports, objective sleep assessments, such as actigraphy and polysomnography (PSG), are important. Actigraphy is an objective and inexpensive procedure for the evaluation of the sleep-wake cycle and can be used in early and later stages of the disease [10] . Actigraphy studies suggest that AD patients have a reduction of sleep efficiency and an increased number of awakenings. Reduction of total sleep time (TST) is not a consistent finding [3, [9] [10] [11] .
Studies using PSG reported alterations in sleep that are observed in the elderly but more severe. A reduction in TST accompanied by an increase of sleep latency, time wake after sleep onset, and the number of awakenings is typical and worsens over the course of the disease [9] . SWS alterations are also observed in AD, reflecting an electroencephalographic slowing that is present also during wakefulness. Interestingly, the density of K-complexes, a neurophysiological hallmark of healthy nonrapid eye movement sleep and considered a forerunner of SWS, is altered in AD patients [9, 12••] .
Another common sleep disorder in AD patients is abnormality of the sleep-wake cycle with reduced amplitude of circadian rhythmicity, phase delay, and sundowning, a condition characterized by a worsening of behavioral and neuropsychiatric symptoms around the time of sunset [13, 14] . These impairments are accompanied by abnormalities in other circadian rhythmicity such as body core temperature, motor activity, and hormone levels that are likely to be associated with the degeneration of the suprachiasmatic nucleus of the hypothalamus where neuropathological changes have documented in AD [15] . Melatonin, a tryptophan metabolite synthesized mainly in the pineal gland and released with circadian rhythmicity, might play a role since its levels are reduced both during aging and in AD [16] . Its anti-oxidative, anti-inflammatory, and antiamyloid properties may have a role in the neuroprotection [17] .
Given the recent evidence that suggests a bidirectional relationship between sleep-wake cycles and AD [5••, 6••, 7, 12] and the negative impact of sleep and circadian impairment on AD patients and caregivers' quality of life and daytime functioning, the identification of effective treatments is of fundamental importance. The challenge now is to find not only therapies to ameliorate patients' symptoms but ideally to find compounds with direct or indirect neuroprotective properties to slowdown cognitive decline by limiting the aggregation of amyloid-β and neurofibrillary tangles.
The following sections summarize the evidence and discuss the latest advances for the therapy of insomnia and circadian rhythm disorders in AD.
Therapy for insomnia in Alzheimer disease
In the well-established bidirectional relationship between insomnia and pathogenesis/progression of AD, scientific interest has been focused on the crucial role of SWS. A considerable body of evidence has demonstrated that NREM SWS fragmentation, amyloid-β accumulation, and cognitive decline are strongly related. In this context, SWS enhancement might represent a potential therapeutic approach.
Several double-blind randomized placebo-controlled studies have tested the efficacy and safety of hypnotic agents such as melatonin, ramelteon, and mirtazapine to treat sleep disorders in AD without significant improvement on sleep parameters. Indeed, results from a recent review [18•] assessing effects of drug treatment versus placebo for sleep disorders in AD suggest that there is no evidence that benzodiazepine, melatonin, and ramelteon are beneficial to AD patients with moderate to severe dementia and sleep problems. Similarly, treatment with mirtazapine or placebo showed no effect on cognitive and functional status as assessed by the Mini-Mental State Examination (MMSE) and the Katz scale respectively in AD patients with sleep disorders [19] . Conversely, a recent study indicates that suvorexant is effective for the treatment of insomnia in patients with AD including improvement of cognitive function [20• ]. In addition, there is promising evidence that trazodone, as an SWS enhancer, improves sleep measures and produces a delayed cognitive decline in long-term treatment [21••] .
Since therapy for insomnia in AD has the potential for improving not only the quality of sleep but also cognitive performance, this review will explore further the association of benzodiazepines and the risk of AD, the possible action of melatonin, and the potential neuroprotective effect of trazodone with a focus on cognition.
Benzodiazepines and related drugs in Alzheimer Disease
Benzodiazepines and related drugs are used most frequently for the treatment of insomnia among older patients including AD. However, the use is associated with a considerable number of side effects, such as daytime sleepiness, worsened insomnia, confusion, and amnesia [18• ]. In addition, there has been a question about a possible association between benzodiazepines and the risk of AD which has been investigated widely without resolution. A body of evidence supports the hypothesis that the use of sedative-hypnotics, especially benzodiazepines, may increase the risk of developing AD pathology.
Billioti de Gage S et al. [22] investigated the association between the use of benzodiazepines and incident dementia in a population-based study of 1063 participants without dementia who did not start taking benzodiazepines until at least the third year of follow-up. They found that the new use of benzodiazepines was associated with an increased risk of dementia of approximately 50%. A retrospective cohort study [23] reported an increased risk of AD among subjects exposed to benzodiazepines, zolpidem, antidepressants, or low-dose antipsychotics regardless of the dose of sedative-hypnotics and half-life among benzodiazepines [23] . Finally, results from a retrospective cohort study demonstrated that the use of a high cumulative dose of zolpidem was associated with an increased risk of AD among older people and suggested caution when considering long-term use of zolpidem in older patients [24] .
On the other hand, there is evidence supporting the opposite hypothesis that the use of benzodiazepines might have a neuroprotective effect on both clinical and pre-clinical AD. A prospective population-based cohort study of 3434 participants without dementia assessed whether higher cumulative use of benzodiazepines was associated with a higher risk of dementia or more rapid cognitive decline [25] . About 23.2% of their participants developed dementia, especially AD, and the risk of dementia was slightly higher in people with minimal exposure to benzodiazepines but not with the highest level of exposure. Their results did not support a causal association between benzodiazepine use and dementia [25] . A nationwide nested case-control study [26] assessing the association between benzodiazepines and the risk of AD using cumulative consumption and duration demonstrated that the use of benzodiazepines was associated with only a modestly increased AD risk. Finally, a case-control study [27] of 1438 incident AD cases examined the association between benzodiazepine use before the AD diagnosis and demonstrated that previous benzodiazepine use was not associated with an increased risk of developing AD.
One question is whether the hypothesis relates to all AD phenotypes. A cross-sectional study [28] of 395 AD patients evaluated the relationship between benzodiazepines and the health status of patients with AD. In particular, the authors assessed the correlations between the prescription of benzodiazepines and patient characteristics such as cognitive and functional capacity, health-related quality of life, and neuropsychiatric symptoms. It showed a higher risk from the benzodiazepine treatment in depressed patients [27] .
A neuroprotective action of benzodiazepines has been supported recently by Pipipenko V et al. in a study of the effects of non-sedating very low and moderate-doses of diazepam in AD model rats [29••] . Diazepam at both doses enhanced spatial learning/memory, prevented neuroinflammation, preserved synaptic plasticity, and normalized the hippocampal and cortical protein expression. These findings might be considered for early pre-dementia stage of human AD.
Melatonin in Alzheimer disease
The use of melatonin for the treatment of sleep disorders in AD is based on the evidence that reduced endogenous melatonin levels may occur in patients in the preclinical stage of the disease [30, 31] . However, there is no evidence that melatonin, either immediate-or slow-release, improved any major sleep outcome in AD [18•]. Indeed, results from a review exploring pharmacotherapies for sleep disturbances in AD reported no difference between melatonin intervention in AD and control groups with respect to total nocturnal sleep time, ratio of daytime sleep to nighttime sleep, sleep efficiency, time awake after sleep onset, or number of nighttime awakenings. In addition, no evidence of improvement on cognition or performance of activities of daily living has been also reported [18•] . Conversely, a randomized, double-blind, parallel-group study [32••] investigated the effects of add-on prolonged-release melatonin (PRM) (2 mg) to standard therapy on cognitive functioning and sleep in mild to moderate AD, with and without insomnia comorbidity. They found that AD patients treated with PRM (24 weeks) had significantly better cognitive performance and sleep efficiency than those treated with placebo, especially in the comorbid insomnia phenotype. On this basis, the authors suggested a possible causal link between poor sleep and cognitive decline in AD [18•]. However, additional longer randomized trials in larger cohorts are needed to validate the use of PRM in patients with AD.
Trazodone in Alzheimer disease
Three studies have demonstrated that trazodone administered at night for 2 weeks significantly improved the quality of the sleep in patients with AD by increasing total nocturnal sleep time and sleep efficiency on actigraphy [33] [34] [35] . Interestingly, a recent literature suggests an association between trazodone use and delayed cognitive decline in AD. Although this association appears to be getting stronger, there are some critical questions. Firstly, what are the neurobiological mechanisms underlying the beneficial effects of trazodone on cognition? Secondly, is there any difference between short-term and long-term use of trazodone on cognitive performance? Thirdly, which cognitive domains are most affected by the effects of trazodone? Despite the ongoing research, these questions remain. With respect to mechanisms of action, it remains unclear whether this relationship is direct or represents an indirect effect of trazodone through improved sleep. Finally, it is acknowledged that there are confounding variables such as concomitant sedative and stimulant medications such as cholinesterase inhibitors (ChEi) that need to be incorporated into the design of new studies.
Three potential biological mechanisms have been proposed to explain the beneficial effects of trazodone on cognition in AD patients: (1) modulation of pathologic amyloid-β aggregation; (2) modulation of tau pathologic burden; and (3) synaptic potentiation via antidepressant (Fig. 1 ). The first two mechanisms have been studied more and seem likely to be involved in the related trazodone benefits.
With respect to the first mechanism, the modulation of amyloid-β aggregation, one question is whether this might be a direct effect of trazodone or indirectly by a sleep-related action. There is good evidence that trazodone is an effective SWS enhancer which supports the hypothesis of an indirect mechanism for its neuroprotective effect [33] [34] [35] . It is noted that in healthy volunteers, trazodone significantly increased the amount of SWS on PSG but there were no changes observed in REM sleep [36] . Similar results have been seen in depressed patients [37] . Supporting the relationship between decreased SWS and amyloid β-pathology and cognitive deficits, animal transgenic models recently found that sleep deprivation increased the amount of amyloid-β pathology in the brain [38] . In addition, in vivo human evidence [6] has demonstrated that β-amyloid burden in the brain was significantly correlated with the severity of impairment in NREM SWS generation, which in turn was associated with impaired overnight memory consolidation.
Taken together, these findings indicate that sleep disruption may be considered a novel pathway contributing to β-amyloid pathologic burden and consequently to cognitive decline. In this context, the well-established enhancement of SWS by trazodone might explain the beneficial effect on cognition via modulation of amyloid-β aggregation.
An alternative or additional mechanism which could explain the beneficial effect of trazodone is related to the modulation of the phosphorylated eukaryotic initiation factor 2-signaling pathway of the unfolded protein response (eIF2-P/UPR) [39] . In the healthy brain, the eIF2 pathway has a crucial role in regulating the synthesis of some proteins needed for learning and memory formation and for maintenance of neuronal integrity: this is an important neuroprotective effect. Supporting the role of the eIF2 pathway is the finding that prolonged overactivation of this pathway seems to be implicated in the neuropathological mechanisms leading to the neurodegeneration in mice models [40, 41] . These findings are also supported by data in humans reporting that the eIF2-P/UPR response is activated in disease-affected brain regions of patients with AD [42] . The accumulation of the phosphorylated form of eIF2 might be also temporally and spatially associated with the deposition of disease-specific misfolded proteins such as tau. In looking for a new therapy to delay cognitive decline, recent studies [39] [40] [41] [42] have evaluated in vitro and in vivo efficacy of two compounds, trazodone hydrochloride and dibenzoylmethane, in reversing eIF2a-P-mediated translational attenuation. They found that both drugs were markedly neuroprotective in two mouse models of neurodegeneration. In addition, trazodone reduced p-tau burden in tauopathy-frontotemporal dementia mice. Of importance, a link between the eIF2-P/UPR pathway and sleep has been observed in mice [43] . Indeed, sleep deprivation with prolonged wakefulness induced activation of the eIF2-P/ UPR response in mouse cerebral cortex.
The third possible biological mechanism for the beneficial effect of trazodone is its antidepressant effect as a selective serotonin reuptake inhibitor and a 5-HT 2 blocker. However, since there is little support for the benefits of antidepressants in AD, it is the least likely mechanism to explain the beneficial effect of trazodone. Firstly, the antidepressant doses of trazodone are usually much higher than doses for insomnia [21] ; Secondly, the effect of antidepressants on SWS are much less robust than their effects on REM sleep suppression [44] ; Thirdly, cognitive performances in geriatric subjects do not improve after acute treatment with antidepressants [45] .
There is limited literature on the short-term use of trazodone in patients with AD. Camargos EF et al. [34] in a randomized, double-blind, placebo-controlled study tested the efficacy and safety of trazodone to treat of sleep disorders in patients with AD. After two 2 weeks of treatment, trazodone improved sleep parameters but unlike some other agents, it had no adverse effect on cognition (Mini-Mental State Examination, forward/backward digit span task, letternumber sequencing, arithmetic, digit symbol-coding, and symbol search) or functionality (Katz index). Camargos EF et al. [35] later confirmed that trazodone 50 mg did not improve cognition after a 2-week treatment period in AD patients. As noted above, a recent study [21••] indicates that long-term use of trazodone in AD might be necessary to achieve a therapeutic effect. The authors [21••] examined in a retrospective subgroup analysis whether long-term use of trazodone was associated with delayed cognitive decline compared with nonusers. Out of a volunteer cohort of over 1000 patients with sleep disturbances, 25 long-term trazodone users were compared with non-users selected by propensity matching. Subjects were grouped diagnostically at their first visit as AD, mild cognitive impairment, and cognitively non-impaired. Their main results were the following: (1) compared with trazodone users, non-users had a significant 2.6-fold faster decline in MMSE, the primary outcome, 0.27 versus 0.70 points per year respectively; (2) trazodone effects on MMSE remained significant comparing AD-predicted pathology users versus non-users, with 2.4fold faster decline in non-users; and ( 3) trazodone effects on all secondary outcomes (processing speed, disability scores, and visual recall) were not statistically different between two groups, although a trend of delayed cognitive decline including short-term visual memory, processing speed, calculations, and phonemic fluency has been reported in users [21••] . The study has major limitations due to the retrospective nature of the study and the lack of power to explore other confounders such as concomitant use of choline esterase inhibitors but it reports the first longitudinal data investigation on AD-predicted pathology patients that supports the association between trazodone use and delayed cognitive decline.
In conclusion, among pharmacotherapies for insomnia in AD, trazodone in the short-term improves the quality of sleep in patients with AD and in longterm use appears to have additional beneficial effects on cognition. The biological mechanisms of longer-term benefits are not known may be through delayed amyloid-β and tau pathologic burden. There is a strong case for large prospective, randomized, controlled clinical trials to evaluate whether long-term treatment with trazodone does delay decline in cognition and to explore the mechanisms by which that might be happening.
Therapy for circadian rhythm disorder in Alzheimer disease
Irregular circadian rhythm disorder [46] is one of the most frequent sleep disorders in AD patients. Circadian dysfunction in AD can manifest in many ways: irregular sleep-wake rhythm disorder, nocturnal sleep fragmentation with excessive awakening during the night, symptoms of insomnia, excessive daytime sleepiness with increased daytime napping, sundowning phenomenon, and nocturnal agitation [47] [48] [49] . In some extreme cases, a complete day/night sleep pattern reversal can be observed [50] . Disturbances in the sleep-wake rhythm can result in institutionalization of these individuals because the impact on the patients and their caregivers is such that care at home is not possible [51] .
As with insomnia, the interaction between circadian disruption and the progression of the disease is likely to be bidirectional with sleep disturbance making AD worse and more severe AD causing sleep disturbances. Early recognition of sleep disturbance and its treatment may help to improve quality of life of patients and caregivers and even modify the course of the disease. The neurobiological basis of circadian disturbances is probably multifactorial [52••] . The main hypothesis is related to neuronal loss in the suprachiasmatic nucleus (SCN) [15, 52••, 53, 54] . In addition, β-amyloid deposits have been shown to directly disrupt the output of the circadian clock, as demonstrated in animal models [55] . As noted in the earlier section on insomnia, sleep deprivation leads to elevations in interstitial spinal fluid levels of β-amyloid, resulting in increased formation of plaques [55] . It is interesting that postmortem studies in AD patients highlighted also retinal and optic nerve tissue pathology [56, 57] in particular loss of retinal ganglion cells (RGCs) and depletion of related axons in the optic nerve [58] . Moreover, a recent study [59] showed β-amyloid deposits within a specific subpopulation of RGCs, the melanopsin RGCs (mRGCs) that, by expressing the photopigment melanopsin, are intrinsically photosensitive and operate as the photoreceptors entraining circadian rhythms to light/dark cycles [60, 61] . The mRGCs send information on external light to the brain through the retinohypothalamic tract [62] , projecting to the SCN of the hypothalamus [63] . Given the key role of mRGCs on circadian rhythms and sleep, the loss and the dysfunctions of this specific cell population may play a central role in the disruption in the circadian rhythm in AD patients. This biological mechanism may be a potential therapeutic target for circadian rhythm disorders in AD patients.
Nonpharmacological approaches are the first-line treatment in AD patients, although there is limited scientific evidence [64•] . Patients with dementia are less active during the day and have reduced social contact and limited exposure to sunlight, with an irregular daily pattern of light and dark. Frequently AD patients live in nursing homes, where the light is constantly on and generally dim [65] . An interesting study evaluated the light exposure in healthy older adults and AD patients during summer and winter [66] , confirming that AD patients are less exposed to light and exhibit lower levels of daily activity, particularly in winter. With this information, an important nonpharmacological approach is establishing proper sleep hygiene practices. [69] [70] [71] [72] .
Bright light therapy (BLT) is the main therapeutic option for sleep and circadian rhythm disorders in patients with dementia. There may also be some effects on cognition, mood, and behavior.
The BLT studies examined different types of artificial bright light (from 1000 to 10,000 lx) delivered in sessions from 1 week to up to 10 weeks. Different duration and timing of the light therapy (morning-lunchtime or afternoon) were tested (Table 1 ). In some studies, a dim light control group was used for comparison [74, 77, 78, 81-83, 85, 87, 92] . Conflicting findings have been reported. This is not surprising since there has been heterogeneity of the treatment sand of the patient population studied such type of dementia and severity of the disease. In addition, sample size varied greatly, usually small. The majority of studies on BLT in dementia patients reported beneficial effects, with improvement in objective or subjective sleep measures, in particular consolidation in nocturnal sleep [69, 74, 76-79, 82, 83, 92] . However, outcomes between studies were very heterogeneous and the number of participants was too small to detect clinically important effects [73-75, 80, 84, 86] . Most of the studies did not specify the dementia type or the differences in the therapeutic effects of BLT based on the dementia type.
Recently, Sekiguchi et al. [93] studied the effect of BLT (approximately 5000 lx) in the morning for 2 weeks in patients with AD, vascular dementia (VaD), and dementia with Lewy body (DLB), showing an improvement of sleep disturbance only in the AD group. Other studies failed to show any sleep improvement, but some demonstrated an increase in the daytime wakefulness [75, 80, 81, [86] [87] [88] [90] [91] [92] . It is important to note that degree of visual impairment or ocular disease, type and severity of dementia, and baseline environmental light exposure can influence the response to the BLT. In addition, compliance with the BLT protocol can influence the efficacy of this intervention. Based on these conflicting findings, there is no consensus regarding the efficacy of the light therapy let alone the best protocol of light intensity, timing, and duration. A recent Cochrane review on the effect of BLT on cognition, sleep, and behavior in dementia patients concluded that there is insufficient evidence to justify the use of bright light therapy in dementia [94•] . More recently, a systematic review and meta-analysis found a small but significant effect of BLT for the treatment of sleep problems such as circadian rhythm sleep disorders, insomnia, and other sleep problems in AD patients or other types of dementia [95••] .
Some studies have evaluated the use of BLT with melatonin, showing improvements in nighttime agitation, sleep efficiency, and daytime somnolence [87, 89] . The combination of melatonin and BLT may be a better approach by targeting multiple routes for circadian entrainment. Also, melatonin alone may serve as a therapeutic agent for treating circadian rhythm disruption: melatonin (3 mg) in the in the evening (20:30) can prolong total sleep time and reduce nighttime activity, without any effect on the daytime naps or activity [96] .
In conclusion, non-pharmacological treatments and bright light therapy may be a useful and safe option for treatment of circadian rhythm disorders in AD patients but there is not adequate evidence to recommend wide use. In addition, there are unsolved issues related to the application of BLT, such as the correct light intensity, the timing and duration of the treatment, or the types of dementia that might benefit most.
Conclusion and future directions
With respect to the therapy for insomnia in AD, the evidence at this stage supports application of good sleep hygiene practices and possibly the use of trazodone to improve the quality of sleep with the potential additional beneficial effects on cognition. The longer term use of trazodone to delay decline in cognition requires large, randomized, controlled trials designed to also investigate the likely mechanism of action. The potential of a new disease-modifying treatment is that it will treat insomnia in patients with dementia but may also delay, possibly prevent, the development of dementia in patients with insomnia.
With respect to circadian rhythm disturbances, there are again nonpharmacological strategies based on good sleep and wake practices. Bright light therapy may be a useful and safe option for the treatment of circadian rhythm disorders in AD. It would be interesting to relate the timing of BLT to the pattern of endogenous melatonin secretion. Further randomized, controlled trials with adequate sample size are needed for confirm the efficacy of BLT.
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